BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 2498378)

  • 21. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Ladrón de Guevara A; Codner E; Preisler J; Crisosto N; Echiburú B; Maliqueo M; Sánchez F; Perez-Bravo F; Cassorla F
    Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss.
    Jakubowicz DJ; Nestler JE
    J Clin Endocrinol Metab; 1997 Feb; 82(2):556-60. PubMed ID: 9024253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations.
    Dale PO; Tanbo T; Vaaler S; Abyholm T
    Fertil Steril; 1992 Sep; 58(3):487-91. PubMed ID: 1521640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
    Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
    Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association of monocyte chemoattractant protein-1 and the clinical characteristics of polycystic ovary syndrome: analysis of 65 cases].
    Hu WH; Qiao J; Li MZ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(11):721-4. PubMed ID: 17565837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
    Nestler JE; Jakubowicz DJ
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Plasma renin and aldosterone levels in obese and non-obese women with polycystic ovary syndrome].
    Mejia-Montilla J; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Bravo-Henríquez A
    Endocrinol Nutr; 2012 Jan; 59(1):21-7. PubMed ID: 22115703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
    Wang A; Li M; Lu C
    Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS.
    Van Dam EW; Roelfsema F; Veldhuis JD; Helmerhorst FM; Frölich M; Meinders AE; Krans HM; Pijl H
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E865-72. PubMed ID: 11882506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
    Garmes HM; Tambascia MA; Zantut-Wittmann DE
    Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of abdominal obesity in patients with polycystic ovary syndrome on metabolic parameters.
    Franik G; Bizoń A; Włoch S; Pluta D; Blukacz Ł; Milnerowicz H; Madej P
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4755-4761. PubMed ID: 29164590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.